Most Liquid Pharmaceuticals Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1NMRA Neumora Therapeutics,
249.03 M
(0.43)
 4.44 
(1.90)
2CTNM Contineum Therapeutics, Class
13.11 M
(0.39)
 4.58 
(1.77)
3ELTX Elicio Therapeutics
11.82 M
(0.01)
 6.01 
(0.07)
4TAK Takeda Pharmaceutical Co
533.53 B
 0.08 
 1.36 
 0.11 
5NVO Novo Nordisk AS
37.47 B
(0.11)
 3.18 
(0.35)
6MRK Merck Company
12.69 B
(0.16)
 2.13 
(0.35)
7SNY Sanofi ADR
6.9 B
 0.06 
 1.68 
 0.11 
8NVS Novartis AG ADR
4.64 B
 0.12 
 1.68 
 0.20 
9ZTS Zoetis Inc
3.58 B
(0.07)
 2.04 
(0.14)
10RDY Dr Reddys Laboratories
2.93 B
(0.11)
 1.89 
(0.21)
11PFE Pfizer Inc
2.85 B
(0.17)
 1.61 
(0.28)
12LLY Eli Lilly and
2.07 B
(0.04)
 2.34 
(0.10)
13RPRX Royalty Pharma Plc
1.47 B
 0.07 
 1.48 
 0.10 
14ARVN Arvinas
1.27 B
(0.14)
 7.66 
(1.08)
15ADGM Adagio Medical Holdings,
21.62 M
 0.03 
 9.35 
 0.29 
16TELO Telomir Pharmaceuticals, Common
1.53 M
(0.09)
 6.42 
(0.61)
17SLNX Solanbridge Group
13.06 K
 0.00 
 0.00 
 0.00 
18IDCN Indocan Resources
219.37
 0.13 
 125.99 
 15.87 
19TEVA Teva Pharma Industries
2.22 B
(0.19)
 3.24 
(0.61)
20CRON Cronos Group
944.89 M
(0.05)
 2.62 
(0.14)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).